Clinical trials: Mantle Cell Lymphoma (MCL)
Mantle Cell Lymphoma
A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL)
The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022.
- Trial name
- NCT03494179
- Testing
- ICP-022
- Where
- 31 sites in China
- Volunteers
- 106 people
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd.
B-cell Lymphoma
Study to Evaluate Adverse Events, Change in Disease Activity, Movement of Oral ABBV-623 and ABBV-992 Tablets in the Body of Adult Participants With B-cell Cancers
B-cell cancer is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- NCT04804254
- Testing
- ABBV-623, ABBV-992
- Where
- 5 sites in Israel, Puerto Rico and 1 more
- Volunteers
- 5 people
- Sponsor
- AbbVie
Mantle Cell Lymphoma
CD19-targeted CAR T Cells for Relapsed and Refractory (R/R) Mantle Cell Lymphoma
This is a phase II, open-label, single-arm, multicenter study to assess the efficacy and safety of JWCAR029 in adult R/R Mantle Cell Lymphoma subjects in China.
- Trial name
- NCT04718883
- Testing
- CD19-targeted Chimeric Antigen Receptor (CAR) T Cells
- Where
- 12 sites in China
- Volunteers
- 59 people
- Sponsor
- Shanghai Ming Ju Biotechnology Co., Ltd.
Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL)
Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell Lymphoma
The study consists of two parts. Part 1 determines the safety and tolerability of sonrotoclax monotherapy, the maximum tolerated dose, and the recommended Phase 2 dose of sonrotoclax monotherapy for relapsed or refractory mantle…
- Conditions
- Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma (MCL), Relapsed Mantle Cell Lymphoma
- Trial name
- NCT05471843
- Testing
- Sonrotoclax
- Where
- 65 sites in United States, Argentina and 12 more
- Volunteers
- 125 people
- Sponsor
- BeOne Medicines
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
This phase I trial studies the side effects and best dose of MORAb-004 in treating young patients with recurrent or refractory solid tumors or lymphoma.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma
- Trial name
- NCT01748721
- Testing
- anti-endosialin/TEM1 monoclonal antibody MORAb-004, pharmacological study, laboratory biomarker analysis
- Where
- 20 sites in United States
- Volunteers
- 27 people
- Sponsor
- Morphotek
Waldenstrom Macroglobulinemia, Multiple Myeloma
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom
Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic…
- Conditions
- Waldenstrom Macroglobulinemia, Multiple Myeloma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
- Trial name
- CLOVER-WaM (NCT02952508)
- Testing
- Iopofosine I 131 single dose, Iopofosine I 131 multiple dose, Iopofosine I 131 fractionated dose
- Where
- 52 sites in United States, Australia and 9 more
- Volunteers
- 120 people
- Sponsor
- Cellectar Biosciences, Inc.
Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.
Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma
To determine if MDX-1411 is safe for the treatment of chronic lymphocytic leukemia or mantle cell lymphoma.
- Trial name
- MDX1411-02 (NCT00730652)
- Testing
- MDX-1411
- Volunteers
- 34 people
- Sponsor
- Bristol-Myers Squibb
Relapsed/Refractory Mantle Cell Lymphoma, Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
The goal of this clinical study is to learn more about KTE-X19, and how safe and effective it is in adult Japanese participants with relapsed/refractory (r/r) Mantle Cell Lymphoma (MCL) or r/r B-precursor Acute Lymphoblastic…
- Trial name
- JKART-1 (NCT06253663)
- Testing
- KTE-X19, Cyclophosphamide, Fludarabine
- Where
- 9 sites in Japan
- Volunteers
- 25 people
- Sponsor
- Kite, A Gilead Company
Myelodysplastic Syndromes, Lymphoma, Mantle-Cell
A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea
The Drug Use Examination (DUE) is planned and designed for the safety evaluation of new indications after the approval of a new drug in Korea.
- Conditions
- Myelodysplastic Syndromes, Lymphoma, Mantle-Cell, Lymphoma, Follicular
- Trial name
- RevlimidPMS (NCT04036448)
- Testing
- REVLIMID®
- Where
- 26 sites in South Korea
- Volunteers
- 28 people
- Sponsor
- Celgene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers
This is an open-label Phase 1b/2 study in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)or non hodgkin's lymphoma (NHL) who have failed prior standard of care therapies including a BTK inhibitor…
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoplasmacytoid Lymphoma, Mantle-Cell Lymphoma
- Trial name
- NCT03037645
- Testing
- SNS-062
- Where
- 11 sites in United States
- Volunteers
- 39 people
- Sponsor
- Sunesis Pharmaceuticals
Non-Hodgkin Lymphoma
Dosimetry Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-02)
This study is a phase I, open label, randomized study to assess pharmacokinetics, biodistribution and radiation dosimetry of lutetium (177Lu) lilotomab satetraxetan (Betalutin®) radioimmunotherapy in patients with relapsed…
- Trial name
- NCT02657447
- Testing
- Betalutin with lilotomab dose 1, Betalutin with lilotomab dose 2
- Where
- Germany
- Sponsor
- Nordic Nanovector
Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL)
Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
The purpose of the project is to set up a national, prospective, longitudinal, multicenter registry platform to document uniform data on characteristics, molecular diagnostics, treatment and course of disease, to collect…
- Conditions
- Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL)
- Trial name
- RUBIN (NCT06043011)
- Testing
- Routine care as per site standard.
- Where
- Germany
- Volunteers
- 2,950 people
- Sponsor
- iOMEDICO AG
Lymphoma, Lymphoma, Mantle-Cell
Study to Evaluate the Safety and Efficacy of IM19 CAR-T Cells in Patients With Relapsed and Refractory (R/R) Mantle Cell Lymphoma
This is a phase I/II, open-label, multicenter study to assess the efficacy and safety of IM19 CAR-T cells in adult R/R Mantle Cell Lymphoma subjects
- Conditions
- Lymphoma, Lymphoma, Mantle-Cell, Neoplasms by Histologic Type, Neoplasms
- Trial name
- NCT05155215
- Testing
- IM19 CAR-T cells, Cyclophosphamide, Fludarabine
- Volunteers
- 68 people
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd.
Mantle-cell Lymphoma
A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in Spain
This is a single-arm, open-label, multicenter, non-indication seeking phase II trial to describe the efficacy and safety of patients with mantle cell lymphoma (MCL) receiving acalabrutinib in combination with R-CHOP for the…
- Trial name
- SOUND-MCL (NCT07029737)
- Testing
- Acalabrutinib + R-CHOP standard of care, Acalabrutinib combination with Rituximab, Acalabrutinib monotherapy
- Where
- 22 sites in Spain
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Lymphoma, Mantle-Cell
An Investigational Study Drug, Palbociclib (PD-0332991), Is Being Studied In Patients With Mantle Cell Lymphoma. Patients Must Have Received Prior Treatment(s) For Mantle Cell Lymphoma.
This is a pilot study evaluating tumor activity using Positron Emission Tomography, which is also known as a "PET scan". This study will assess the safety of using PD-0332991 in patients with mantle cell lymphoma.
- Trial name
- NCT00420056
- Testing
- PD-0332991
- Where
- 6 sites in United States
- Volunteers
- 17 people
- Sponsor
- Pfizer
Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma
A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies
Protocol YY-20394-007 is a phase1 open-label, single-arm, multi-centre study to assess the safety and efficacy of YY-20394 in participants with relapse and/or refractory B cell malignant hematological tumor.
- Conditions
- Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
- Trial name
- NCT04279405
- Testing
- YY-20394
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Shanghai YingLi Pharmaceutical Co. Ltd.
Mantle Cell Lymphoma
A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL
Compare the efficacy and safety of Orelabrutinib plus bendamustine+ rituximab versus bendamustine + rituximab in previously untreated patients with mantle cell lymphoma (MCL)
- Trial name
- NCT06363994
- Testing
- Orelabrutinib, Bendamustine Injection, Rituximab
- Where
- 39 sites in China
- Volunteers
- 476 people
- Sponsor
- InnoCare Pharma Inc.
Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific
MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma
RATIONALE: MP470 may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This clinical trial is studying the side effects and best dose of MP470 in treating patients with unresectable…
- Trial name
- NCT00504205
- Testing
- multitargeted receptor tyrosine kinase inhibitor MP470, laboratory biomarker analysis, pharmacological study
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Lymphoma, Mantle-Cell
Phase IIa Study of Copanlisib in Relapsed or Refractory Mantle Cell Lymphoma (MCL)
The primary objective of this study is to assess objective response rate (ORR) in patients with relapsed or refractory MCL who failed ibrutinib treatment or were unable to tolerate ibrutinib.
- Trial name
- NCT02455297
- Testing
- Copanlisib (BAY80-6946)
- Where
- 5 sites in United States
- Volunteers
- 4 people
- Sponsor
- Bayer
B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed
RPM CD19-mbIL15-CAR-T Cells in Patient With Advanced Lymphoid Malignancies
This is an open-label Phase 1 study to determine the feasibility, safety, and the recommended maximum tolerated Dose (MTD) of a single infusion of RPM CD19 mbIL15 CAR-T cells for adult patients.
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Primary Mediastinal Large B Cell Lymphoma
- Trial name
- NCT04844086
- Testing
- RPM CD19-mbIL15-CAR-T cells
- Where
- Taiwan
- Volunteers
- 2 people
- Sponsor
- Eden BioCell Ltd.